Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and Technology company, today announced that it has signed an agreement to acquire the Duolink® product portfolio from Olink Bioscience.
The acquisition includes intellectual property, sales, marketing and manufacturing assets.
The newly acquired product line is designed for researchers studying biological pathways and seeking improved sensitivity to uncover disease biomarkers. Since 2013, Sigma-Aldrich has distributed Duolink reagents, along with pre-validated antibody pairs for proximity ligation assays (in situ PLA®).
“We are excited about the acquisition of the Duolink product portfolio. Duolink is valuable to our customers and complements the rest of Sigma-Aldrich’s Protein Biology portfolio,” said Amanda Halford, Vice President, Academic Research at Sigma-Aldrich. “Owning the Duolink technology will provide Sigma-Aldrich with opportunities to develop new products, as well as advance our existing technologies.”
Duolink Technology, based on PLA technology, enables researchers to visualize low levels of proteins, protein modifications and individual protein interactions directly in fixed cells and tissue samples without the need for overexpression. This technology can significantly enhance the rigor and reproducibility of scientific experiments, aided by dual recognition of antibody pairs.
“Duolink has been a very important product in the history and development of Olink, and we feel that with this acquisition by Sigma-Aldrich, it will be in very good hands and continue to be a great success,” said Jon Heimer, CEO of Olink Bioscience. “We will now focus our resources on further developing our Proseek® Multiplex product line for human protein biomarker research, as well as expanding our global presence by establishing local commercial organizations in Europe and North America, and continuing to develop new innovative tools for the scientific community.”
“Duolink technology is transforming the way scientists study biological pathways. It allows interactions between proteins at the endogenous levels to now be visualized, providing researchers with reproducible data they can see,” said Halford. “The acquisition of Duolink allows Sigma-Aldrich to provide comprehensive solutions for enabling experimental reproducibility, with continued reliability in supply and quality.”
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.